Skip to main content

Table 3 Odds ratios of MetS risk factors by hsCRP and sRAGE categories in men (n = 712) a

From: Higher serum soluble receptor for advanced glycation end product levels and lower prevalence of metabolic syndrome among Japanese adult men: a cross-sectional study

 

Crude

Model 1c

  

MetS

Odds ratio (95% CI)

P b

Odds ratio (95% CI)

P b

  

Higher hsCRP/lower sRAGE (n = 192)

1

 

1

   

Higher hCRP/higher sRAGE (n = 161)

0.65 (0.42–1.01)

0.057

0.60 (0.37–0.95)

0.031

  

Lower hsCRP/lower sRAGE (n = 164)

0.26 (0.16–0.43)

<0.001

0.26 (0.15–0.43)

<0.001

  

Lower hsCRP/higher sRAGE (n = 195)

0.16 (0.09–0.27)

<0.001

0.16 (0.09–0.28)

<0.001

  
 

Crude

Model 1 c

Model 4 d

Central obesity

Odds ratio (95% CI)

P b

Odds ratio (95% CI)

P b

Odds ratio (95% CI)

P b

Higher hsCRP/lower sRAGE (n = 192)

1

 

1

 

1

 

Higher hCRP/higher sRAGE (n = 161)

0.56 (0.36–0.87)

0.010

0.50 (0.31–0.79)

0.003

0.56 (0.35–0.92)

0.020

Lower hsCRP/lower sRAGE (n = 164)

0.38 (0.24–0.61)

<0.001

0.38 (0.23–0.61)

<0.001

0.48 (0.30–0.80)

0.004

Lower hsCRP/higher sRAGE (n = 195)

0.17 (0.10–0.28)

<0.001

0.15 (0.09–0.26)

<0.001

0.21 (0.12–0.37)

<0.001

 

Crude

Model 1 c

Model 4 d

Elevated BP

Odds ratio (95% CI)

P b

Odds ratio (95% CI)

P b

Odds ratio (95% CI)

P b

Higher hsCRP/lower sRAGE (n = 192)

1

 

1

 

1

 

Higher hCRP/higher sRAGE (n = 161)

0.40 (0.26–0.63)

<0.001

0.43 (0.26–0.71)

0.001

0.49 (0.30–0.83)

0.007

Lower hsCRP/lower sRAGE (n = 164)

0.47 (0.30–0.73)

0.001

0.41 (0.25–0.67)

<0.001

0.54 (0.32–0.90)

0.019

Lower hsCRP/higher sRAGE (n = 195)

0.24 (0.16–0.37)

<0.001

0.25 (0.15–0.40)

<0.001

0.35 (0.21–0.58)

<0.001

 

Crude

Model 1 c

Model 4 d

Elevated FBG

Odds ratio (95% CI)

P b

Odds ratio (95% CI)

P b

Odds ratio (95% CI)

P b

Higher hsCRP/lower sRAGE (n = 192)

1

 

1

 

1

 

Higher hCRP/higher sRAGE (n = 161)

0.75 (0.48–1.16)

0.20

0.87 (0.54–1.39)

0.56

1.04 (0.64–1.68)

0.88

Lower hsCRP/lower sRAGE (n = 164)

0.51 (0.32–0.80)

0.004

0.50 (0.31–0.81)

0.005

0.61 (0.37–1.00)

0.050

Lower hsCRP/higher sRAGE (n = 195)

0.47 (0.30–0.73)

0.001

0.60 (0.38–0.96)

0.031

0.86 (0.52–1.42)

0.56

 

Crude

Model 1 c

Model 4 d

Elevated TG

Odds ratio (95% CI)

P b

Odds ratio (95% CI)

P b

Odds ratio (95% CI)

P b

Higher hsCRP/lower sRAGE (n = 192)

1

 

1

 

1

 

Higher hCRP/higher sRAGE (n = 161)

0.91 (0.59–1.39)

0.66

0.86 (0.54–1.32)

0.46

1.01 (0.63–1.63)

0.96

Lower hsCRP/lower sRAGE (n = 164)

0.52 (0.34–0.82)

0.004

0.55 (0.35–0.84)

0.011

0.77 (0.47–1.25)

0.29

Lower hsCRP/higher sRAGE (n = 195)

0.34 (0.21–0.53)

<0.001

0.34 (0.21–0.54)

<0.001

0.53 (0.32–0.89)

0.015

 

Crude

Model 1 c

Model 4 d

Reduced HDL-C

Odds ratio (95% CI)

P b

Odds ratio (95% CI)

P b

Odds ratio (95% CI)

P b

Higher hsCRP/lower sRAGE (n = 192)

1

 

1

 

1

 

Higher hCRP/higher sRAGE (n = 161)

1.09 (0.65–1.82)

0.76

0.78 (0.45–1.38)

0.40

0.79 (0.43–1.47)

0.46

Lower hsCRP/lower sRAGE (n = 164)

0.35 (0.18–0.68)

0.002

0.39 (0.19–0.77)

0.007

0.44 (0.21–0.93)

0.032

Lower hsCRP/higher sRAGE (n = 195)

0.34 (0.18–0.64)

0.001

0.27 (0.14–0.54)

<0.001

0.37 (0.18–0.78)

0.009

  1. aParticipants were categorized by the median values (1259.0 pg/mL for sRAGE; 0.38 mg/L for hsCRP). CI, confidential interval ; sRAGE, soluble receptor of advanced glycation end-products; BP, blood pressure; FBG, fasting blood glucose; TG, triglyceride; HDL-C, high density lipoprotein cholesterol.
  2. bMultiple logistic regression analysis.
  3. cAdjusted for age (continuous variable), smoking status (never, former, or current), drinking status (never, ≤ 3 day(s)/week, 4–6 days/week, or every day), educational level (≥college or not), occupation (desk work or non-desk work), depressive symptoms (Self-Rating Depression Scale ≥40 or not), physical activity (<1.0 METs · hour/week, 1.0–22.9 METs · hour/week, or ≥23.0 METs · hour/week), total energy intake (continuous variable), sleep time (≥6 and ≤8 hours/day or not), and eGFR (continuous variable).
  4. dAdditionally adjusted for mutual metabolic syndrome components.
Back to article page

Diabetology & Metabolic Syndrome

ISSN: 1758-5996

Contact us